EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1

References

• Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212 - 36; http://dx.doi.org/10.3322/caac.20121; PMID: 21685461
   PubMed Web of Science ®Google Scholar
• Moss C, Kaye SB. Ovarian cancer: progress and continuing controversies in management. Eur J Cancer 2002; 38:1701 - 7; http://dx.doi.org/10.1016/S0959-8049(02)00161-2; PMID: 12175685
   PubMed Web of Science ®Google Scholar
• Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011; 61:183 - 203; http://dx.doi.org/10.3322/caac.20113; PMID: 21521830
   PubMed Web of Science ®Google Scholar
• Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25:1329 - 33; http://dx.doi.org/10.1200/JCO.2006.09.1066; PMID: 17416853
   PubMed Web of Science ®Google Scholar
• Khoo US, Chan KY, Cheung AN, Xue WC, Shen DH, Fung KY, Ngan HY, Choy KW, Pang CP, Poon CS, et al. Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population. Hum Mutat 2002; 19:307 - 8; http://dx.doi.org/10.1002/humu.9015; PMID: 11857749
   PubMedGoogle Scholar
• Russell PA, Pharoah PD, De Foy K, Ramus SJ, Symmonds I, Wilson A, Scott I, Ponder BA, Gayther SA. Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. Int J Cancer 2000; 87:317 - 21; http://dx.doi.org/10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B; PMID: 10897034
   PubMed Web of Science ®Google Scholar
• Kuzmichev A, Jenuwein T, Tempst P, Reinberg D. Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol Cell 2004; 14:183 - 93; http://dx.doi.org/10.1016/S1097-2765(04)00185-6; PMID: 15099518
   PubMed Web of Science ®Google Scholar
• Czermin B, Melfi R, McCabe D, Seitz V, Imhof A, Pirrotta V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 2002; 111:185 - 96; http://dx.doi.org/10.1016/S0092-8674(02)00975-3; PMID: 12408863
   PubMed Web of Science ®Google Scholar
• Müller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, Miller EL, O’Connor MB, Kingston RE, Simon JA. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 2002; 111:197 - 208; http://dx.doi.org/10.1016/S0092-8674(02)00976-5; PMID: 12408864
   PubMed Web of Science ®Google Scholar
• Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439:871 - 4; http://dx.doi.org/10.1038/nature04431; PMID: 16357870
   PubMed Web of Science ®Google Scholar
• Yang X, Karuturi RK, Sun F, Aau M, Yu K, Shao R, Miller LD, Tan PB, Yu Q. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One 2009; 4:e5011; http://dx.doi.org/10.1371/journal.pone.0005011; PMID: 19340297
   PubMed Web of Science ®Google Scholar
• Fujii S, Ito K, Ito Y, Ochiai A. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 2008; 283:17324 - 32; http://dx.doi.org/10.1074/jbc.M800224200; PMID: 18430739
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Jacinto FV, Villanueva A, Fernandez AF, Yamamoto H, Carmona FJ, Puertas S, Marquez VE, Shinomura Y, Imai K, et al. Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer. Oncogene 2012; 31:1988 - 94; http://dx.doi.org/10.1038/onc.2011.387; PMID: 21892211
   PubMed Web of Science ®Google Scholar
• Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003; 100:11606 - 11; http://dx.doi.org/10.1073/pnas.1933744100; PMID: 14500907
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624 - 9; http://dx.doi.org/10.1038/nature01075; PMID: 12374981
   PubMed Web of Science ®Google Scholar
• Weikert S, Christoph F, Köllermann J, Müller M, Schrader M, Miller K, Krause H. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 2005; 16:349 - 53; PMID: 16012774
   PubMed Web of Science ®Google Scholar
• Guo J, Cai J, Yu L, Tang H, Chen C, Wang Z. EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo. Cancer Sci 2011; 102:530 - 9; http://dx.doi.org/10.1111/j.1349-7006.2010.01836.x; PMID: 21205084
   PubMed Web of Science ®Google Scholar
• Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, Xiao L, Wang Z. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 2010; 10:788 - 95; http://dx.doi.org/10.4161/cbt.10.8.12913; PMID: 20686362
   PubMed Web of Science ®Google Scholar
• Scully R, Ganesan S, Brown M, De Caprio JA, Cannistra SA, Feunteun J, Schnitt S, Livingston DM. Location of BRCA1 in human breast and ovarian cancer cells. Science 1996; 272:123 - 6; http://dx.doi.org/10.1126/science.272.5258.123; PMID: 8600523
   PubMed Web of Science ®Google Scholar
• Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, Karlan BY. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 2000; 60:5329 - 33; PMID: 11034065
   PubMed Web of Science ®Google Scholar
• Plo I, Laulier C, Gauthier L, Lebrun F, Calvo F, Lopez BS. AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51. Cancer Res 2008; 68:9404 - 12; http://dx.doi.org/10.1158/0008-5472.CAN-08-0861; PMID: 19010915
   PubMed Web of Science ®Google Scholar
• Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, Ljungman M, Merajver SD, Kleer CG. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 2009; 28:843 - 53; http://dx.doi.org/10.1038/onc.2008.433; PMID: 19079346
   PubMed Web of Science ®Google Scholar
• Gonzalez ME, DuPrie ML, Krueger H, Merajver SD, Ventura AC, Toy KA, Kleer CG. Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Cancer Res 2011; 71:2360 - 70; http://dx.doi.org/10.1158/0008-5472.CAN-10-1933; PMID: 21406404
   PubMed Web of Science ®Google Scholar
• Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998; 58:1120 - 3; PMID: 9515792
   PubMed Web of Science ®Google Scholar
• Chen G, Gharib TG, Huang CC, Taylor JMG, Misek DE, Kardia SLR, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002; 1:304 - 13; http://dx.doi.org/10.1074/mcp.M200008-MCP200; PMID: 12096112
   PubMed Web of Science ®Google Scholar
• Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999; 19:1720 - 30; PMID: 10022859
   PubMed Web of Science ®Google Scholar
• Yang J-Y, Hung M-C. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res 2009; 15:752 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-08-0124; PMID: 19188143
   PubMed Web of Science ®Google Scholar
• Zhou BP, Liao Y, Xia W, Spohn B, Lee M-H, Hung M-C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001; 3:245 - 52; http://dx.doi.org/10.1038/35060032; PMID: 11231573
   PubMed Web of Science ®Google Scholar
• Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999; 286:1162 - 6; http://dx.doi.org/10.1126/science.286.5442.1162; PMID: 10550055
   PubMed Web of Science ®Google Scholar
• Xu B, Kim St, Kastan MB. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 2001; 21:3445 - 50; http://dx.doi.org/10.1128/MCB.21.10.3445-3450.2001; PMID: 11313470
   PubMed Web of Science ®Google Scholar
• Yasmeen A, Liu W, Dekhil H, Kassab A, Aloyz R, Foulkes WD, Al Moustafa AE. BRCA1 mutations contribute to cell motility and invasion by affecting its main regulators. Cell Cycle 2008; 7:3781 - 3; http://dx.doi.org/10.4161/cc.7.23.6993; PMID: 19098453
   PubMed Web of Science ®Google Scholar
• Wang Y, Yu J, Zhan Q. BRCA1 regulates caveolin-1 expression and inhibits cell invasiveness. Biochem Biophys Res Commun 2008; 370:201 - 6; http://dx.doi.org/10.1016/j.bbrc.2008.03.031; PMID: 18343216
   PubMed Web of Science ®Google Scholar
• Puppe J, Drost R, Liu X, Joosse SA, Evers B, Cornelissen-Steijger P, Nederlof P, Yu Q, Jonkers J, van Lohuizen M, et al. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res 2009; 11:R63; http://dx.doi.org/10.1186/bcr2354; PMID: 19709408
   PubMed Web of Science ®Google Scholar
• Du J, Li L, Ou Z, Kong C, Zhang Y, Dong Z, Zhu S, Jiang H, Shao Z, Huang B, et al. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells. Breast Cancer Res Treat 2012; 131:65 - 73; http://dx.doi.org/10.1007/s10549-011-1396-3; PMID: 21465172
   PubMed Web of Science ®Google Scholar
• Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani R-S, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008; 27:7274 - 84; http://dx.doi.org/10.1038/onc.2008.333; PMID: 18806826
   PubMed Web of Science ®Google Scholar
• Zeidler M, Varambally S, Cao Q, Chinnaiyan AM, Ferguson DO, Merajver SD, Kleer CG. The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia 2005; 7:1011 - 9; http://dx.doi.org/10.1593/neo.05472; PMID: 16331887
   PubMed Web of Science ®Google Scholar
• Baumann P, Benson FE, West SC. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 1996; 87:757 - 66; http://dx.doi.org/10.1016/S0092-8674(00)81394-X; PMID: 8929543
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402 - 8; http://dx.doi.org/10.1006/meth.2001.1262; PMID: 11846609
   PubMed Web of Science ®Google Scholar
• Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47:936 - 42; PMID: 3802100
   PubMed Web of Science ®Google Scholar